1. Home
  2. SUPN vs CXM Comparison

SUPN vs CXM Comparison

Compare SUPN & CXM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • CXM
  • Stock Information
  • Founded
  • SUPN 2005
  • CXM 2009
  • Country
  • SUPN United States
  • CXM United States
  • Employees
  • SUPN N/A
  • CXM 3589
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • CXM Computer Software: Prepackaged Software
  • Sector
  • SUPN Health Care
  • CXM Technology
  • Exchange
  • SUPN Nasdaq
  • CXM Nasdaq
  • Market Cap
  • SUPN 1.8B
  • CXM 2.1B
  • IPO Year
  • SUPN 2012
  • CXM 2021
  • Fundamental
  • Price
  • SUPN $31.92
  • CXM $8.24
  • Analyst Decision
  • SUPN Hold
  • CXM Hold
  • Analyst Count
  • SUPN 2
  • CXM 14
  • Target Price
  • SUPN $36.00
  • CXM $9.79
  • AVG Volume (30 Days)
  • SUPN 467.8K
  • CXM 1.0M
  • Earning Date
  • SUPN 05-06-2025
  • CXM 06-04-2025
  • Dividend Yield
  • SUPN N/A
  • CXM N/A
  • EPS Growth
  • SUPN N/A
  • CXM 144.44
  • EPS
  • SUPN 1.11
  • CXM 0.44
  • Revenue
  • SUPN $667,997,000.00
  • CXM $796,394,000.00
  • Revenue This Year
  • SUPN N/A
  • CXM $4.24
  • Revenue Next Year
  • SUPN $8.74
  • CXM $5.47
  • P/E Ratio
  • SUPN $28.64
  • CXM $19.18
  • Revenue Growth
  • SUPN 11.82
  • CXM 8.74
  • 52 Week Low
  • SUPN $25.53
  • CXM $6.75
  • 52 Week High
  • SUPN $40.28
  • CXM $11.79
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 44.01
  • CXM 56.59
  • Support Level
  • SUPN $31.56
  • CXM $7.97
  • Resistance Level
  • SUPN $32.85
  • CXM $8.27
  • Average True Range (ATR)
  • SUPN 0.78
  • CXM 0.17
  • MACD
  • SUPN -0.11
  • CXM 0.01
  • Stochastic Oscillator
  • SUPN 5.23
  • CXM 64.23

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About CXM Sprinklr Inc.

Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.

Share on Social Networks: